MX2015014190A - Construccion de adn inmunomoduladora no codificante cerrada covalentemente. - Google Patents

Construccion de adn inmunomoduladora no codificante cerrada covalentemente.

Info

Publication number
MX2015014190A
MX2015014190A MX2015014190A MX2015014190A MX2015014190A MX 2015014190 A MX2015014190 A MX 2015014190A MX 2015014190 A MX2015014190 A MX 2015014190A MX 2015014190 A MX2015014190 A MX 2015014190A MX 2015014190 A MX2015014190 A MX 2015014190A
Authority
MX
Mexico
Prior art keywords
dna construct
covalently closed
closed non
immunomodulatory dna
coding
Prior art date
Application number
MX2015014190A
Other languages
English (en)
Inventor
Christiane Kleuss
Kerstin Kapp
Burghardt Wittig
Matthias Schroff
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of MX2015014190A publication Critical patent/MX2015014190A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una construcción de ADN inmunomoduladora cerrada covalentemente, una composición farmacéutica y una vacuna así como su uso en la modulación del sistema inmune. Proporciona una construcción de ADN para inmunomodulación que comprende una secuencia específica de ADN.
MX2015014190A 2014-02-18 2015-02-18 Construccion de adn inmunomoduladora no codificante cerrada covalentemente. MX2015014190A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1402847.6A GB2523187A (en) 2014-02-18 2014-02-18 Covalently closed non-coding immunomodulatory DNA construct
PCT/EP2015/053396 WO2015124614A1 (en) 2014-02-18 2015-02-18 Covalently closed non-coding immunomodulatory dna construct

Publications (1)

Publication Number Publication Date
MX2015014190A true MX2015014190A (es) 2015-12-11

Family

ID=50440342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014190A MX2015014190A (es) 2014-02-18 2015-02-18 Construccion de adn inmunomoduladora no codificante cerrada covalentemente.

Country Status (16)

Country Link
US (1) US10280424B2 (es)
EP (1) EP2999787B1 (es)
JP (1) JP6067893B2 (es)
KR (1) KR101831713B1 (es)
CN (1) CN105264074A (es)
AU (1) AU2015220911B2 (es)
BR (1) BR112015025748A2 (es)
CA (1) CA2908522A1 (es)
DK (1) DK2999787T3 (es)
ES (1) ES2634002T3 (es)
GB (1) GB2523187A (es)
HK (1) HK1216758A1 (es)
MX (1) MX2015014190A (es)
RU (1) RU2668387C2 (es)
SG (1) SG11201508108YA (es)
WO (1) WO2015124614A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) * 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
SG11202001683SA (en) 2017-08-31 2020-03-30 Mologen Ag Tlr-9 agonists for modulation of tumor microenvironment
US20230323343A1 (en) * 2020-01-31 2023-10-12 Tyris Therapeutics, S.L. Closed linear dna with modified nucleotides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
EP1539215A2 (en) * 2002-06-25 2005-06-15 City of Hope Adjuvant-free peptide vaccine
EP1605972A2 (en) * 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
KR101107818B1 (ko) 2003-10-30 2012-01-31 콜레이 파마시티컬 그룹, 인코포레이티드 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체
PT1699480E (pt) 2003-12-30 2011-08-30 Mologen Ag AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO
WO2005080567A1 (de) * 2004-02-20 2005-09-01 Mologen Ag Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
WO2006015560A1 (de) * 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
BRPI0711607A2 (pt) 2006-05-11 2012-11-06 Mologen Ag molécula multimérica para modulação da atividade do sistema imunológico humano ou animal, agente de combinação, kit, agente farmacêutico, molécula e uso da mesma
WO2010039137A1 (en) 2008-10-02 2010-04-08 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
EP2246433A1 (de) 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct

Also Published As

Publication number Publication date
GB201402847D0 (en) 2014-04-02
HK1216758A1 (zh) 2016-12-02
GB2523187A (en) 2015-08-19
WO2015124614A1 (en) 2015-08-27
DK2999787T3 (en) 2017-08-07
US20160348114A1 (en) 2016-12-01
EP2999787A1 (en) 2016-03-30
RU2668387C2 (ru) 2018-09-28
CA2908522A1 (en) 2015-08-27
JP2016526373A (ja) 2016-09-05
EP2999787B1 (en) 2017-04-19
CN105264074A (zh) 2016-01-20
US10280424B2 (en) 2019-05-07
KR101831713B1 (ko) 2018-02-23
JP6067893B2 (ja) 2017-01-25
ES2634002T3 (es) 2017-09-26
SG11201508108YA (en) 2015-10-29
KR20150130425A (ko) 2015-11-23
AU2015220911B2 (en) 2017-02-02
AU2015220911A1 (en) 2015-10-15
BR112015025748A2 (pt) 2017-10-10
RU2015140720A (ru) 2017-03-29

Similar Documents

Publication Publication Date Title
MX2015014190A (es) Construccion de adn inmunomoduladora no codificante cerrada covalentemente.
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
PL3207053T3 (pl) Nowe peptydy immunogenne
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
MD20170032A2 (ro) Anticorpi anti-TIGIT
NZ766131A (en) Antibodies binding axl
EP3112378A4 (en) Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
ZA201608394B (en) Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
MY191539A (en) Streptococcal vaccine
IL251120B (en) Immunogenic/therapeutic glycoside preparations and their uses
EP3194595A4 (en) Viral rna segments as immunomodulatory agents and vaccine components
PL3223796T3 (pl) Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania
EP3178491A4 (en) Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
IL262731A (en) Therapeutic hpv vaccine combinations
IL252683A0 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
GB201713163D0 (en) HPV vaccine
EP3228707A4 (en) Vector containing centromere dna sequence and use thereof
EP3194451A4 (en) Treatment of tumours using peptide-protein conjugates
EP3169354A4 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
EP3178839A4 (en) Cdca1-derived peptide and vaccine containing same
EP3137111A4 (en) Compositions and methods for intradermal vaccine delivery
EP3332809A4 (en) COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND PHARMACEUTICAL VACCINE COMPOSITION
EP3178837A4 (en) Urlc10-derived peptide and vaccine containing same
PT3534936T (pt) Vacina de adn tolerogénica